<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39267168</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-6511</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>BMC pharmacology &amp; toxicology</Title><ISOAbbreviation>BMC Pharmacol Toxicol</ISOAbbreviation></Journal><ArticleTitle>Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.</ArticleTitle><Pagination><StartPage>64</StartPage><MedlinePgn>64</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">64</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40360-024-00789-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Numerous digestive system adverse events (dsAEs) have been observed during the use of anti-obesity medications (AOMs), leading to concerns about the safety of these medications. However, most current studies are limited to the association of one class of drugs with specific digestive disorders, and there is no cascading analysis of AOMs in the digestive system. This study aims to use data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) for a stratified analysis of the reported associations between AOMs and dsAEs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed adverse event reports submitted to FAERS between January 2015 and December 2023 related to obesity treatment. It is important to note that FAERS data cannot establish causality or incidence rates. Pharmacovigilance (PV) signals were detected by disproportionate analyses through proportionate reporting ratio (PRR), reporting odds ratios (ROR), and information components (IC) to detect dsAEs associated with AOMs. Reporting rates, severity, and response outcomes of digestive adverse events were compared across AOMs by multivariate logistic regression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 34,396 adverse events (AEs) related to obesity treatment, 8844 dsAEs were analyzed. Comparing with semaglutide and liraglutide, tirzepatide exhibited fewer reported dsAEs while semaglutide and liraglutide showed a high correlation with non-lethal pancreatitis reports. Bupropion-naltrexone (31.65%) reported the highest number of dsAEs, and a PV signal was detected in mouth and lips AEs (ROR = 2.97, 95% CI: 2.42-3.6). Orlistat (ROR = 3.30, 95% CI: 3.08-3.55) exhibited the highest association with gastrointestinal AEs compared to other AOMs. PV signal for hepatobiliary AEs (ROR = 6.13, 95% CI: 3.45-10.88) with phentermine-topiramate still needs further clarification.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tirzepatide may be considered for patients with a history of digestive system disease or an elevated risk of pancreatitis based on the pattern of reported dsAEs. Caution is needed for the orofacial AEs when using bupropion-naltrexone. Orlistat has a higher reporting rate of gastrointestinal AEs, but these events are typically less severe. Phentermine-topiramate's association with liver impairment requires further clinical investigation. This article provides insights into the reported associations between AOMs and dsAEs, which may aid clinicians in making more informed decisions about individualizing medication and managing potential adverse events.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Laboratory of Mitochondria and Metabolism, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Menghuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Huaihe Hospital of Henan University, No. 8, Baobei Road, Gulou District, Kaifeng, 475000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qin-Qin</ForeName><Initials>QQ</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Laboratory of Mitochondria and Metabolism, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China. heqinqin2022@wchscu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Pharmacol Toxicol</MedlineTA><NlmUniqueID>101590449</NlmUniqueID><ISSNLinking>2050-6511</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019440">Anti-Obesity Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>839I73S42A</RegistryNumber><NameOfSubstance UI="D000069450">Liraglutide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019440" MajorTopicYN="Y">Anti-Obesity Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="Y">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004066" MajorTopicYN="N">Digestive System Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069450" MajorTopicYN="N">Liraglutide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-obesity medications</Keyword><Keyword MajorTopicYN="N">Digestive adverse events</Keyword><Keyword MajorTopicYN="N">Disproportionality analysis</Keyword><Keyword MajorTopicYN="N">FDA adverse event reporting system database</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>15</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>0</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>12</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39267168</ArticleId><ArticleId IdType="pmc">PMC11391863</ArticleId><ArticleId IdType="doi">10.1186/s40360-024-00789-9</ArticleId><ArticleId IdType="pii">10.1186/s40360-024-00789-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.</Citation></Reference><Reference><Citation>Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet (London England). 2017;390(10113):2627–42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5735219</ArticleId><ArticleId IdType="pubmed">29029897</ArticleId></ArticleIdList></Reference><Reference><Citation>World obesity atlas. 2023. https://data.worldobesity.org/publications/?cat=19.</Citation></Reference><Reference><Citation>Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Global Health. 2022;7(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494015</ArticleId><ArticleId IdType="pubmed">36130777</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–66. 10.1056/NEJMra1514009</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1514009</ArticleId><ArticleId IdType="pubmed">28099824</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet (London England). 2011;378(9793):804–14. 10.1016/S0140-6736(11)60813-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60813-1</ArticleId><ArticleId IdType="pubmed">21872749</ArticleId></ArticleIdList></Reference><Reference><Citation>Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98.10.1038/s41574-019-0176-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-019-0176-8</ArticleId><ArticleId IdType="pubmed">30814686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan D, Heaner M. Guidelines (2013) for managing overweight and obesity in adults. Preface to the full report. Obes (Silver Spring Md). 2014;22(Suppl 2):S1–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">24961822</ArticleId></ArticleIdList></Reference><Reference><Citation>National Clinical Guideline Centre. National Institute for Health and Care Excellence: guidelines. In: Obesity: identification, assessment and management of overweight and obesity in children, young people and adults: partial update of CG43. edn. London: National Institute for Health and Care Excellence (NICE), National Clinical Guideline Centre; 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">25535639</ArticleId></ArticleIdList></Reference><Reference><Citation>Frühbeck G, Toplak H, Woodward E, Halford JC, Yumuk V. Need for a paradigm shift in adult overweight and obesity management - an EASO position statement on a pressing public health, clinical and scientific challenge in Europe. Obes Facts. 2014;7(6):408–16. 10.1159/000370038</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000370038</ArticleId><ArticleId IdType="pmc">PMC5644793</ArticleId><ArticleId IdType="pubmed">25503968</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai AG, Bessesen DH. Obesity. Ann Intern Med. 2019;170(5):Itc33–48. 10.7326/AITC201903050</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC201903050</ArticleId><ArticleId IdType="pubmed">30831593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, Yin X, Xu Q. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521.10.3389/fendo.2023.1161521</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1161521</ArticleId><ArticleId IdType="pmc">PMC10161731</ArticleId><ArticleId IdType="pubmed">37152942</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsuhibani A, Thompson JR, Wigle PR, Guo JJ, Lin AC, Rao MB, Hincapie AL. Metabolic and bariatric surgery utilization trends in the United States: evidence from 2012 to 2021 national electronic medical records network %U. Annals Surg Open. 2023;4(4):e317. https://journals.lww.com/aosopen/fulltext/2023/12000/metabolic_and_bariatric_surgery_utilization_trends.28.aspx.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10735086</ArticleId><ArticleId IdType="pubmed">38144499</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–87. 10.1001/jama.2020.12567</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12567</ArticleId><ArticleId IdType="pubmed">32870301</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa K, Schneeweiss S, Kim DW, Patorno E. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States. Diabetes Obes Metab. 2021;23(7):1542–51. 10.1111/dom.14367</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14367</ArticleId><ArticleId IdType="pubmed">33651454</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198–225. 10.1053/j.gastro.2022.08.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.08.045</ArticleId><ArticleId IdType="pubmed">36273831</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolen-Doerr E, Stockman MC, Rizo I. Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity. Curr Obes Rep. 2019;8(3):284–91. 10.1007/s13679-019-00350-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13679-019-00350-4</ArticleId><ArticleId IdType="pubmed">31124035</ArticleId></ArticleIdList></Reference><Reference><Citation>Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs. 2006;66(12):1625–56. 10.2165/00003495-200666120-00012</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200666120-00012</ArticleId><ArticleId IdType="pubmed">16956313</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig SL, Keating GM. Naltrexone ER/Bupropion ER: a review in obesity management. Drugs. 2015;75(11):1269–80. 10.1007/s40265-015-0427-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-015-0427-5</ArticleId><ArticleId IdType="pubmed">26105116</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA. Combination phentermine and topiramate extended release in the management of obesity. Expert Opin Pharmacother. 2015;16(8):1263–74. 10.1517/14656566.2015.1041505</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2015.1041505</ArticleId><ArticleId IdType="pubmed">25958964</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker TJA. Tirzepatide once Weekly for the treatment of obesity. N Engl J Med. 2022;387(15):1433. 10.1056/NEJMc2211120</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2211120</ArticleId><ArticleId IdType="pubmed">36239652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795–7. 10.1001/jama.2023.19574</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.19574</ArticleId><ArticleId IdType="pmc">PMC10557026</ArticleId><ArticleId IdType="pubmed">37796527</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Obes Rev Official J Int Association Study Obes. 2022;23(6):e13435.10.1111/obr.13435</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.13435</ArticleId><ArticleId IdType="pubmed">35194917</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsuhibani A, Alrasheed M, Gari M, Hincapie AL, Guo JJ. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA adverse event reporting system (FAERS) databases 2013–2020. Int J Clin Pharm. 2022;44(1):172–9. 10.1007/s11096-021-01330-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-021-01330-2</ArticleId><ArticleId IdType="pubmed">34564826</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver J, Willy M, Avigan M. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS J. 2008;10(1):35–41. 10.1208/s12248-007-9004-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-007-9004-5</ArticleId><ArticleId IdType="pmc">PMC2751449</ArticleId><ArticleId IdType="pubmed">18446503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, Liu Z, Cheng Q, Zhang J, Luo P. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 2023;59:101967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10149185</ArticleId><ArticleId IdType="pubmed">37131541</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada M, Fujimoto M, Yamazaki K, Takamoto M, Hosomi K. Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database. Drug Saf. 2014;37(6):421–31. 10.1007/s40264-014-0163-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-014-0163-x</ArticleId><ArticleId IdType="pubmed">24743876</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhang HM, Jiang Y, Wen Z, Bao EH, Huang J, Wang CJ, Chen CX, Wang JH, Yang XS. Cardiovascular adverse events associated with new-generation androgen receptor pathway inhibitors (ARPI) for prostate Cancer: a disproportionality analysis based on the FDA adverse event reporting System (FAERS). Clin Genitourin Cancer. 2023;21(5):594–601e592. 10.1016/j.clgc.2023.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clgc.2023.07.003</ArticleId><ArticleId IdType="pubmed">37482524</ArticleId></ArticleIdList></Reference><Reference><Citation>Saladin KS, McFarland RK. Human anatomy. Volume 2. McGraw-Hill New York; 2008.</Citation></Reference><Reference><Citation>Park G, Jung H, Heo SJ, Jung I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance. Life (Basel Switzerland). 2020;10(8).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460123</ArticleId><ArticleId IdType="pubmed">32764444</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, et al. The REporting of a disproportionality analysis for DrUg Safety Signal Detection using individual Case Safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585–99. 10.1007/s40264-024-01423-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-024-01423-7</ArticleId><ArticleId IdType="pmc">PMC11116264</ArticleId><ArticleId IdType="pubmed">38713347</ArticleId></ArticleIdList></Reference><Reference><Citation>Subeesh V, Maheswari E, Gr S, Swaroop AM, Minnikanti SS. A comparative study of Data Mining Algorithms used for Signal Detection in FDA AERS Database. J Young Pharmacists. 2018.</Citation></Reference><Reference><Citation>Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM. A standardized dataset of a spontaneous adverse event reporting system. Healthc (Basel Switzerland). 2022;10(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8954498</ArticleId><ArticleId IdType="pubmed">35326898</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J. Obesity meets its match. Sci (New York NY). 2023;382(6676):1226–7.10.1126/science.adn4691</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adn4691</ArticleId><ArticleId IdType="pubmed">38096291</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev Official J Int Assoc Study Obes. 2023;24(3):e13543.10.1111/obr.13543</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.13543</ArticleId><ArticleId IdType="pubmed">36579723</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL, van Raalte DH. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016;18(3):224–35. 10.1111/dom.12593</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12593</ArticleId><ArticleId IdType="pubmed">26500045</ArticleId></ArticleIdList></Reference><Reference><Citation>Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–6. 10.1053/j.gastro.2011.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.02.018</ArticleId><ArticleId IdType="pmc">PMC4404515</ArticleId><ArticleId IdType="pubmed">21334333</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England). 2010;376(9741):595–605. 10.1016/S0140-6736(10)60888-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)60888-4</ArticleId><ArticleId IdType="pubmed">20673995</ArticleId></ArticleIdList></Reference><Reference><Citation>Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obes (Silver Spring Md). 2013;21(5):935–43.10.1002/oby.20309</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.20309</ArticleId><ArticleId IdType="pmc">PMC3739931</ArticleId><ArticleId IdType="pubmed">23408728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sternby B, Hartmann D, Borgström B, Nilsson A. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine. Clin Nutr. 2002;21(5):395–402. 10.1054/clnu.2002.0565</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/clnu.2002.0565</ArticleId><ArticleId IdType="pubmed">12381337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhou J, Xu S, Liu M, Wang M, Ma Y, Zhao M, Wang Z, Guo Y, Zhao L. Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity. Biochem Pharmacol. 2019;170:113669. 10.1016/j.bcp.2019.113669</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2019.113669</ArticleId><ArticleId IdType="pubmed">31628911</ArticleId></ArticleIdList></Reference><Reference><Citation>Phentermine-Topiramate. In. LiverTox: clinical and Research Information on Drug-Induced Liver Injury. edn. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">31643176</ArticleId></ArticleIdList></Reference><Reference><Citation>Perdomo CM, Cohen RV, Sumithran P, Clément K, Frühbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet (London England). 2023;401(10382):1116–30. 10.1016/S0140-6736(22)02403-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02403-5</ArticleId><ArticleId IdType="pubmed">36774932</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events Associated with Immune Checkpoint Blockade in patients with Cancer: a systematic review of Case Reports. PLoS ONE. 2016;11(7):e0160221. 10.1371/journal.pone.0160221</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0160221</ArticleId><ArticleId IdType="pmc">PMC4966895</ArticleId><ArticleId IdType="pubmed">27472273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>